Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Garg

Showing results (501-510 of 530) with videos related to

Pageof 53
Sort By:
Clinical Pharmacology in Drug Development|July 14, 2016
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA PatientsTong Zhu, James Keirns, Corrie Howieson, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2019
Delays and barriers to early treatment initiation for childhood tuberculosis in IndiaC Valvi, A Chandanwale, S Khadse, et al.
Global Heart|May 28, 2015
Heart Disease Is Associated With Anthropometric Indices and Change in Body Size Perception Over the Life Course: The Golestan Cohort StudyVaani P Garg, Rajesh Vedanthan, Farhad Islami, et al.
AJNR. American Journal of Neuroradiology|June 1, 2019
Ensemble of Convolutional Neural Networks Improves Automated Segmentation of Acute Ischemic Lesions Using Multiparametric Diffusion-Weighted MRIS Winzeck, S J T Mocking, R Bezerra, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 14, 2021
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical TrialYaacov Frishberg, Georges Deschênes, Jaap W Groothoff, et al.
The New England Journal of Medicine|February 10, 2025
Efficacy and Safety of Obinutuzumab in Active Lupus NephritisRichard A Furie, Brad H Rovin, Jay P Garg, et al.
The New England Journal of Medicine|March 6, 2026
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus ErythematosusRichard A Furie, Maria Dall'Era, Edward M Vital, et al.
The New England Journal of Medicine|March 31, 2021
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1Sander F Garrelfs, Yaacov Frishberg, Sally A Hulton, et al.
The New England Journal of Medicine|July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.
The New England Journal of Medicine|October 27, 2023
Patisiran Treatment in Patients with Transthyretin Cardiac AmyloidosisMathew S Maurer, Parag Kale, Marianna Fontana, et al.
Pageof 53

Showing results (501-510 of 530) with videos related to

Sort By:
Pageof 53
Clinical Pharmacology in Drug Development|July 14, 2016
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA PatientsTong Zhu, James Keirns, Corrie Howieson, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2019
Delays and barriers to early treatment initiation for childhood tuberculosis in IndiaC Valvi, A Chandanwale, S Khadse, et al.
Global Heart|May 28, 2015
Heart Disease Is Associated With Anthropometric Indices and Change in Body Size Perception Over the Life Course: The Golestan Cohort StudyVaani P Garg, Rajesh Vedanthan, Farhad Islami, et al.
AJNR. American Journal of Neuroradiology|June 1, 2019
Ensemble of Convolutional Neural Networks Improves Automated Segmentation of Acute Ischemic Lesions Using Multiparametric Diffusion-Weighted MRIS Winzeck, S J T Mocking, R Bezerra, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 14, 2021
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical TrialYaacov Frishberg, Georges Deschênes, Jaap W Groothoff, et al.
The New England Journal of Medicine|February 10, 2025
Efficacy and Safety of Obinutuzumab in Active Lupus NephritisRichard A Furie, Brad H Rovin, Jay P Garg, et al.
The New England Journal of Medicine|March 6, 2026
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus ErythematosusRichard A Furie, Maria Dall'Era, Edward M Vital, et al.
The New England Journal of Medicine|March 31, 2021
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1Sander F Garrelfs, Yaacov Frishberg, Sally A Hulton, et al.
The New England Journal of Medicine|July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.
The New England Journal of Medicine|October 27, 2023
Patisiran Treatment in Patients with Transthyretin Cardiac AmyloidosisMathew S Maurer, Parag Kale, Marianna Fontana, et al.
Pageof 53